Ticarex 90mg (Ticagrelor)

Adult dose

Acute coronary syndrome: Administer an initial dose of 180mg, followed by 90mg twice daily. Treatment for 12 months is recommended unless discontinuation is clinically necessary. Patients taking this medication should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. In patients with acute coronary syndrome who have undergone percutaneous coronary intervention (PCI) and are at increased risk of bleeding, monotherapy with this medication (discontinuing aspirin) may be considered after 3 months of concomitant treatment with this medication and aspirin. Patients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of thrombotic cardiovascular events: Administer 60mg twice daily. Patients taking this medication should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients who took 90mg of this medication or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with 60mg of this medication. Treatment with this medication may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). The safety and efficacy of this medication were evaluated at 3 years of follow-up. Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg twice daily. Patients taking this medication should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. For patients with acute coronary syndrome, refer to the corresponding dosage and administration instructions. Data on the safety and efficacy of this medication for use beyond 3 years are limited. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180mg, followed by 90mg twice daily for 30 days. Patients taking this medication should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended for patients with acute ischemic stroke or high-risk transient ischemic attack. This medication is administered orally and may be taken with or without food. For patients who have difficulty swallowing tablets, crush this medication into a fine powder, disperse it in half a glass of water, and drink the mixture. Rinse the glass with another half glass of water and drink it. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the tube with water after administration. When switching from another antiplatelet agent to this medication, start this medication 24 hours after the last dose of the previous medication. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dose adjustment is necessary in patients with renal impairment. No dose adjustment is necessary in patients with mild hepatic impairment. This medication has not been studied in patients with severe hepatic impairment, and experience in patients with moderate hepatic impairment is limited.

Child dose

The safety and efficacy in pediatric patients under 18 years of age have not been established.

This medication prevents platelets in the blood from aggregating to form clots, thereby reducing the risk of cardiovascular diseases such as myocardial infarction or stroke due to thrombosis. However, it can increase the risk of bleeding and should not be administered to patients with current bleeding or a history of intracranial hemorrhage. Patients scheduled for surgery should discontinue this medication at least 5 days prior to the procedure and consult with their physician regarding the risk of bleeding during or after surgery. It is crucial to exercise caution when using this medication alongside other drugs that may increase bleeding risk, and immediate medical attention should be sought if bleeding symptoms occur. Patients experiencing bradycardia or arrhythmia symptoms need to be cautious when taking this medication, and medical evaluation should be sought if relevant symptoms arise. Patients with asthma or chronic obstructive pulmonary disease should consult with their physician before taking this medication as respiratory distress symptoms may occur. Women who are pregnant or planning pregnancy should avoid becoming pregnant while taking this medication, and breastfeeding mothers should consult with a physician to decide on breastfeeding. This medication is not recommended for use in children under 18 years, as its safety and efficacy have not been established. Overdosage may increase the risk of bleeding, so it is important to take the medication as directed and avoid excess doses. The risk of side effects may increase when used with certain liver disease patients or strong CYP3A4 inhibitors, so patients must inform healthcare providers about all medications currently being taken before starting this medication. Due to potential dizziness or confusion, patients should be cautious when driving or operating machinery while experiencing such symptoms.

• Hemorrhage
• intracranial hemorrhage
• ocular hemorrhage
• ear hemorrhage
• hypotension
• respiratory distress
• respiratory tract hemorrhage
• gastrointestinal hemorrhage
• diarrhea
• nausea

This medication must be stored in a tightly sealed container to protect it from air and moisture. It is advisable to maintain the storage temperature between 1 and 30 degrees Celsius.

Appearance

Yellow, bilaterally convex, round film-coated tablet

Package unit

60 tablets/box [(10 tablets/PTP x 6)]